iTeos Therapeutics (ITOS) Projected to Post Quarterly Earnings on Thursday

Key Points

• iTeos Therapeutics (ITOS) is expected to report Q2 2025 earnings on August 14, with analysts predicting a loss of $0.94 per share.
• The stock price opened at $10.11 and has experienced significant fluctuations over the past year, with a 12-month low of $4.80 and a high of $18.13.
• Recent insider activity includes major shareholder Bioventures selling over 630,000 shares and CEO Michel Detheux disposing of 43,883 shares, reflecting a 22.19% decrease in his ownership.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect iTeos Therapeutics to post earnings of ($0.94) per share for the quarter.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.51) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.39). On average, analysts expect iTeos Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

iTeos Therapeutics Stock Performance

Shares of NASDAQ ITOS traded down $0.02 during trading hours on Friday, reaching $10.11. 1,018,707 shares of the stock were exchanged, compared to its average volume of 1,639,603. The firm has a market capitalization of $386.95 million, a price-to-earnings ratio of -2.16 and a beta of 1.49. iTeos Therapeutics has a 52 week low of $4.80 and a 52 week high of $18.13. The stock's fifty day simple moving average is $10.12 and its 200 day simple moving average is $8.16.

Wall Street Analyst Weigh In

ITOS has been the topic of a number of recent research reports. Raymond James Financial set a $12.00 price objective on iTeos Therapeutics in a research note on Wednesday, May 14th. JPMorgan Chase & Co. lowered iTeos Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $15.00 to $8.00 in a research note on Tuesday, May 13th. Leerink Partnrs downgraded iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 14th. Wedbush reissued an "outperform" rating and set a $10.50 price objective (down previously from $12.00) on shares of iTeos Therapeutics in a report on Monday, July 21st. Finally, Piper Sandler downgraded iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, July 21st. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $15.50.

Insider Activity at iTeos Therapeutics

In related news, CEO Michel Detheux sold 43,883 shares of the business's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total value of $439,707.66. Following the completion of the sale, the chief executive officer directly owned 153,903 shares of the company's stock, valued at $1,542,108.06. The trade was a 22.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the sale, the insider directly owned 2,108,594 shares of the company's stock, valued at $16,995,267.64. The trade was a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,939,307 shares of company stock valued at $16,202,116 in the last three months. Corporate insiders own 12.50% of the company's stock.

Institutional Trading of iTeos Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio purchased a new position in shares of iTeos Therapeutics in the 1st quarter worth approximately $31,000. Dynamic Technology Lab Private Ltd bought a new stake in iTeos Therapeutics during the 1st quarter valued at $67,000. Jane Street Group LLC raised its holdings in iTeos Therapeutics by 117.1% during the 1st quarter. Jane Street Group LLC now owns 21,438 shares of the company's stock valued at $128,000 after acquiring an additional 147,107 shares during the period. Finally, AQR Capital Management LLC increased its holdings in shares of iTeos Therapeutics by 88.6% in the first quarter. AQR Capital Management LLC now owns 226,210 shares of the company's stock worth $1,350,000 after purchasing an additional 106,260 shares during the period. 97.16% of the stock is owned by institutional investors.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.